Compounds > ibuprofen

ibuprofen and clemastine

ibuprofen has been researched along with clemastine in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Burkhart, GA; Freiman, J1
Crowell, SP; Ellis, BE; Hertz, RP; Louv, W; Moyé, L; Pratt, CM1

Reviews

1 review(s) available for ibuprofen and clemastine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for ibuprofen and clemastine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
The risk of life-threatening cardiovascular events with terfenadine.
    The American journal of cardiology, 1995, Jan-15, Volume: 75, Issue:2

    Topics: Arrhythmias, Cardiac; Clemastine; Humans; Ibuprofen; Risk Factors; Terfenadine; Ventricular Dysfunction

1995
Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine.
    The American journal of cardiology, 1994, Feb-15, Volume: 73, Issue:5

    Topics: Adult; Age Factors; Aged; Arrhythmias, Cardiac; Clemastine; Cohort Studies; Death, Sudden, Cardiac; Disease; Drug-Related Side Effects and Adverse Reactions; Female; Heart Arrest; Humans; Ibuprofen; Information Systems; Male; Middle Aged; Nonprescription Drugs; Product Surveillance, Postmarketing; Prospective Studies; Risk Factors; Terfenadine; Ventricular Function

1994